I-Tech AB (SE:ITECH)
:ITECH
Top Page
I-Tech AB
(ITECH)
Select Model
Select Model
Rating:68Neutral
Price Target:
kr54.00
▲(0.37% Upside)
Action:DowngradedDate:02/08/26
The score is supported by strong financial performance (high profitability, low leverage, solid cash generation) and reasonable valuation with a ~4% dividend yield. These positives are materially offset by weak technicals, with the stock trading far below key moving averages and negative momentum/oversold indicators.
Positive Factors
Conservative balance sheet
Extremely low or no debt across recent years gives I-Tech durable financial flexibility. This reduces refinancing and solvency risk, supports investment in commercialization or R&D, and allows the firm to sustain operations and strategic initiatives through industry cycles without leverage-driven constraints.
Negative Factors
2025 revenue decline & margin drop
A year-over-year revenue decline in 2025 combined with sharper gross-margin erosion signals structural sensitivity to pricing, product mix, or cost pressures. If sustained, shrinking top-line and margins would weaken cash flow conversion, reduce reinvestment capacity, and make profits more fragile over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Extremely low or no debt across recent years gives I-Tech durable financial flexibility. This reduces refinancing and solvency risk, supports investment in commercialization or R&D, and allows the firm to sustain operations and strategic initiatives through industry cycles without leverage-driven constraints.
Read all positive factors
I-Tech AB (ITECH) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr596.29M
Dividend Yield3.31%
Average Volume (3M)30.18K
Price to Earnings (P/E)24.5
Beta (1Y)-0.24
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees11
SectorTechnology
Sector Strength88
IndustryBiotechnology
Share Statistics
EPS (TTM)0.62
Shares Outstanding11,997,777
10 Day Avg. Volume43,174
30 Day Avg. Volume30,179
Financial Highlights & Ratios
PEG Ratio-1.25
Price to Book (P/B)3.58
Price to Sales (P/S)3.71
P/FCF Ratio9.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.44
Revenue Forecast (FY)kr178.50M
I-Tech AB Business Overview & Revenue Model
Company Description
I-Tech AB, a bio-technology company, develops and commercializes fouling prevention products in Sweden. The company offers Selektope, a bio-repellent ingredient for marine coatings that provide hard fouling prevention for ships. Selektope prevent ...
How the Company Makes Money
I-Tech makes money primarily by selling its antifouling biocide ingredient/technology (commonly referenced as Selektope®) into the marine coatings value chain. Revenue is generated when marine coating formulators and paint manufacturers purchase t...
I-Tech AB Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
88
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 168.12M | 179.45M | 120.86M | 83.63M | 52.90M |
| Gross Profit | 44.59M | 95.22M | 63.54M | 45.13M | 27.48M |
| EBITDA | 50.77M | 54.31M | 30.34M | 18.06M | 1.60M |
| Net Income | 33.19M | 39.01M | 20.20M | 10.62M | -2.65M |
Balance Sheet | |||||
| Total Assets | 193.73M | 173.11M | 152.44M | 125.41M | 115.12M |
| Cash, Cash Equivalents and Short-Term Investments | 148.16M | 100.16M | 83.26M | 52.75M | 35.01M |
| Total Debt | 0.00 | 7.79M | 0.00 | 2.25M | 4.29M |
| Total Liabilities | 19.35M | 15.73M | 16.20M | 9.37M | 10.19M |
| Stockholders Equity | 174.39M | 157.39M | 136.24M | 116.03M | 104.94M |
Cash Flow | |||||
| Free Cash Flow | 64.19M | 35.04M | 32.76M | 20.06M | -2.43M |
| Operating Cash Flow | 64.60M | 35.17M | 35.14M | 20.13M | -1.70M |
| Investing Cash Flow | -409.00K | -408.00K | -2.38M | -822.00K | -928.00K |
| Financing Cash Flow | -16.20M | -17.86M | -2.25M | -1.56M | -3.35M |
I-Tech AB Peers Comparison
UnderperformOutperform
Sector (61)
SE:ITECH
I-Tech AB
49.70
-31.83
-39.04%
SE:ONCO
Oncopeptides AB
1.40
-0.08
-5.47%
DE:8F8
SynAct Pharma AB
1.58
0.04
2.73%
DE:30S
Saniona AB
1.49
0.96
177.18%
DE:6XP
Xspray Pharma AB
2.43
0.17
7.62%
DE:7V3
Cantargia AB
0.35
0.26
282.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.